Mark Lawler, Chair in Translational Cancer Genomics at Queen’s University Belfast, shared on LinkedIn:
“In addition to the Lancet Oncology Commission itself, that we launched in Hong Kong at the Union for International Cancer Control (UICC) World Cancer Congress, there is also a significant body of work that has provided the evidence base to support this initiative.
A series of 18 supporting publications make this the most comprehensive evaluation of precision oncology ever undertaken. Critically, these data inform a tiered approach that makes the case for pragmatic precision medicine for all.”
Other posts featuring Mark Lawler on OncoDaily.